Dr. Sabari on Immunotherapy Updates in Small Cell Lung Cancer

Joshua Sabari, MD
Published: Friday, Oct 14, 2016



Joshua Sabari, MD, medical oncology fellow, Memorial Sloan Kettering Cancer Center, discusses recent findings in immunotherapy as potential treatment for patients with small cell lung cancer (SCLC). Sabari shared these insights during an interview at the 2016 IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology.

Recent clinical trial findings demonstrated strong antitumor activity with the PD-1 inhibitor nivolumab (Opdivo), as well as combination therapy with nivolumab and the CTLA-4 inhibitor ipilimumab (Yervoy). Further studies are ongoing to shed light on the activity of this and other combinations, Sabari explains.

This leads to a promising era in the field of SCLC, as there, historically, have been less effective treatment options. FDA approvals of such treatments could improve quality of life for patients.


Joshua Sabari, MD, medical oncology fellow, Memorial Sloan Kettering Cancer Center, discusses recent findings in immunotherapy as potential treatment for patients with small cell lung cancer (SCLC). Sabari shared these insights during an interview at the 2016 IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology.

Recent clinical trial findings demonstrated strong antitumor activity with the PD-1 inhibitor nivolumab (Opdivo), as well as combination therapy with nivolumab and the CTLA-4 inhibitor ipilimumab (Yervoy). Further studies are ongoing to shed light on the activity of this and other combinations, Sabari explains.

This leads to a promising era in the field of SCLC, as there, historically, have been less effective treatment options. FDA approvals of such treatments could improve quality of life for patients.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x